SCHEMBL5664709

SCHEMBL5664709

O=C(O)c1cccc2cccc(Cl)c12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.70
MEN1 O00255 3/20 0.70
KMT2A Q03164 3/20 0.70
HSD17B10 Q99714 2/20 0.70
TSHR P16473 2/20 0.70
KDM4E B2RXH2 1/20 0.70
RXFP1 Q9HBX9 1/20 0.70
NR4A1 P22736 1/20 0.52
NR4A2 P43354 1/20 0.52
NR4A3 Q92570 1/20 0.52
PBRM1 Q86U86 2/20 0.49
CYP1A2 P05177 2/20 0.48
ALOX15 P16050 1/20 0.48
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
USP2 O75604 1/20 0.46
MT-CO2 P00403 1/20 0.46
LMNA P02545 1/20 0.46
TTR P02766 1/20 0.46
PLA2G1B P04054 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6915789 0.98 ALDH1A1 (0.68) ALDH1A1MEN1KMT2AHSD17B10TSHR
SCHEMBL6915887 0.98 ALDH1A1 (0.68) ALDH1A1MEN1KMT2AHSD17B10TSHR
SCHEMBL6915788 0.98 ALDH1A1 (0.68) ALDH1A1MEN1KMT2AHSD17B10TSHR
SCHEMBL6916678 0.98 ALDH1A1 (0.68) ALDH1A1MEN1KMT2AHSD17B10TSHR
SCHEMBL6909969 0.98 ALDH1A1 (0.68) ALDH1A1MEN1KMT2AHSD17B10TSHR
SCHEMBL6913595 0.98 ALDH1A1 (0.68) ALDH1A1MEN1KMT2AHSD17B10TSHR
SCHEMBL6916682 0.98 ALDH1A1 (0.68) ALDH1A1MEN1KMT2AHSD17B10TSHR
SCHEMBL6916880 0.98 ALDH1A1 (0.68) ALDH1A1MEN1KMT2AHSD17B10TSHR
SCHEMBL6918684 0.98 ALDH1A1 (0.68) ALDH1A1MEN1KMT2AHSD17B10TSHR
SCHEMBL6909967 0.98 ALDH1A1 (0.68) ALDH1A1MEN1KMT2AHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630552-B2 Inhibitors of KRAS G12C BEONE MEDICINES I GMBH (CH) 2026-05-19 US disclosed
US-20220389021-A1 INHIBITORS OF KRAS G12C BEONE MEDICINES I GMBH (CH) 2022-12-08 US disclosed
CN-114929706-A Inhibitors of KRAS G12C 百济神州有限公司 2022-08-19 CN disclosed
WO-2022067462-A1 PROCESS FOR PREPARING INHIBITORS OF KRAS G12C BEIGENE (BEIJING) CO., LTD. (CN) 2022-04-07 WO disclosed
WO-2021058018-A1 INHIBITORS OF KRAS G12C BEIGENE, LTD. (KY) 2021-04-01 WO disclosed
EP-2465841-A1 Preparation of esters of mono- or dicarboxylic non-aromatic and aromatic acids Lonza Ltd. (CH) 2012-06-20 EP disclosed
US-20060128823-A1 Radiation curable inkjet recording ink, and method of producing planographic printing plate using same, and ink composition, inkjet recording method, printed material, method of producing a planographic printing plate, and planographic printing plate FUJI PHOTO FILM CO., LTD. 2006-06-15 US disclosed
EP-1657286-A2 Radiation curable ink jet ink, comprising a polymerisation initiation sensitising dye FUJI PHOTO FILM CO., LTD. (JP) 2006-05-17 EP disclosed
US-4224225-A PHOTOPOLYMERIZATION INITIATOR FUJI PHOTO FILM CO., LTD. (JP) 1980-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220389021-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS ALDH1A1 3777/4885MEN1 895/4885KMT2A 2234/4885
US-12630552-B2 Inhibitors of KRAS G12C KRAS, NRAS, HRAS ALDH1A1 1940/4885MEN1 1397/4885KMT2A 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.